Dr Bridget Bannerman is a member of the Operations Board for the Alliance for Cancer Early Detection (ACED), a member of the Early Cancer Institute steering committee in Cambridge, and the Programme Manager for the ACED cohort.
She is also a Research Professor at the University of Sierra Leone piloting initiatives in global health and digital education. Dr Bannerman has a PhD in Biochemistry from the University of Cambridge, and an MSc in Informatics from the University of Manchester, and specialises in evolutionary and theoretical systems biology. She has previously led/supported multiple clinical trials, held research management positions at the Cambridge University Hospitals and the Medical Research Council, and postdoc positions in drug discovery at the Cambridge University Departments of Biochemistry and Medicine. Over the years, she has led institutional projects sponsored by Pfizer, Takeda, Movetis (a spin-off from Johnson and Johnson), Royal Society, WHO, and various CROs at the MRC, Wellcome Trust Sanger Institute, University of Cambridge, and hospitals. As a champion of diversity in clinical trials, Dr Bannerman has spearheaded patient engagement and recruitment strategies across diverse populations in Africa, Europe, and the Americas.
